(Q41251318)

28 September 2017

Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer? (English)

1 reference

28 September 2017

B Seckin

1

1 reference

28 September 2017

C T Anthony

series ordinal

2

1 reference

28 September 2017

B Murphy

series ordinal

3

1 reference

28 September 2017

M S Steiner

series ordinal

4

1 reference

28 September 2017

1 January 1996

1 reference

28 September 2017

World Journal of Urology

1 reference

28 September 2017

14 Suppl 1

1 reference

28 September 2017

S26-9

1 reference

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

28 September 2017

1 reference

12 December 2020

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer

1 reference

12 December 2020

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

12 December 2020

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer

1 reference

12 December 2020

Effect of Suramin on Human Prostate Cancer Cells in Vitro

1 reference

12 December 2020

Structural characterization and biological functions of fibroblast growth factor

1 reference

12 December 2020

Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil

1 reference

12 December 2020

Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer

1 reference

12 December 2020

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

1 reference

12 December 2020

PAP and PSA in prostatic carcinoma cell lines and aspiration biopsies: relation to hormone sensitivity and to cytological grading

1 reference

12 December 2020

Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study

1 reference

12 December 2020

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

12 December 2020

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

The clinical usefulness of prostate specific antigen: update 1994.

1 reference

12 December 2020

The use of adriamycin and its derivatives in the treatment of prostatic cancer

1 reference

12 December 2020

Oral etoposide in the treatment of hormone-refractory prostate cancer.

1 reference

12 December 2020

Identifiers

0 references

1 reference